Introduction:
Ambiguous standards lead to differences in clinical practice among different centers dealing with sarcoidosis.

Aim and objectives:
To describe our local cohort in terms of demography, clinical data, diagnostic procedures, and treatment decisions.

Methods
We made a survey of our ILD database to screen for patients with a final diagnosis of sarcoidosis. Demography, radiological findings, organ involvement, lung function tests, and necessity of therapy were analyzed. All patients were diagnosed according to current guidelines.

Results:
The study included 181 sarcoidosis patients hospitalized between 2019 and 2022 (27.8% of entire ILD group). There was higher proportion of men (57.5%), 56.4% of patients were in the range of 41 - 60 years. Loefgren (LS) or Heerfordt (HS) syndromes were found in 17.3%. 43% were classified as radiological stage II and 41.1% as stage I. Multiple organ involvement was confirmed in 26.6% of patients. Bronchial obstruction (BO) was present in 10.2% of patients with 1 hospitalization and in 33.3% with multiple admissions. Multiple admissions were linked to multiorgan involvement. Desaturation in 6-minute walking test (6MWT) was detected in 11.1% of those with 1 hospitalization and in 41.2% of those with multiple hospital stays. Systemic treatment was recommended to 12.3% of discharged patients. Treated patients frequently had extrapulmonary involvement, were males (65.2%), of the age between 42-60 years (60.9%), with radiological stage IV (39.1%) or II (30.4%).

Conclusions:
We identified risk factors for the need of systemic treatment and readmissions. Based on our results and current standards we are proposing the diagnostic algorithm.